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BACKGROUND
BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed the 
safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-
cell leukemia that had relapsed after treatment with a purine analogue or who had 
disease that was refractory to purine analogues.
METHODS
We conducted two phase 2, single-group, multicenter studies of vemurafenib (at a 
dose of 960 mg twice daily) — one in Italy and one in the United States. The 
therapy was administered for a median of 16 weeks in the Italian study and 18 weeks 
in the U.S. study. Primary end points were the complete response rate (in the Italian 
trial) and the overall response rate (in the U.S. trial). Enrollment was completed 
(28 patients) in the Italian trial in April 2013 and is still open (26 of 36 planned 
patients) in the U.S. trial.
RESULTS
The overall response rates were 96% (25 of 26 patients who could be evaluated) 
after a median of 8 weeks in the Italian study and 100% (24 of 24) after a median of 
12 weeks in the U.S. study. The rates of complete response were 35% (9 of 26 pa-
tients) and 42% (10 of 24) in the two trials, respectively. In the Italian trial, after 
a median follow-up of 23 months, the median relapse-free survival was 19 months 
among patients with a complete response and 6 months among those with a par-
tial response; the median treatment-free survival was 25 months and 18 months, 
respectively. In the U.S. trial, at 1 year, the progression-free survival rate was 73% 
and the overall survival rate was 91%. Drug-related adverse events were usually of 
grade 1 or 2, and the events most frequently leading to dose reductions were rash 
and arthralgia or arthritis. Secondary cutaneous tumors (treated with simple exci-
sion) developed in 7 of 50 patients. The frequent persistence of phosphorylated 
ERK–positive leukemic cells in bone marrow at the end of treatment suggests 
bypass reactivation of MEK and ERK as a resistance mechanism.
CONCLUSIONS
A short oral course of vemurafenib was highly effective in patients with relapsed or 
refractory hairy-cell leukemia. (Funded by the Associazione Italiana per la Ricerca 
sul Cancro and others; EudraCT number, 2011-005487-13; ClinicalTrials.gov number 
NCT01711632.)
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Hairy-cell leukemia is a chronic mature B-cell cancer with unique clinico-pathologic and biologic features.1-4 Purine 
analogues (cladribine and pentostatin) induce 
durable complete responses in approximately 
80% of patients with this cancer.5,6 However, in 
30 to 50% of patients, the disease relapses and 
there is a progressively worse response to purine 
analogues,7,8 which can also cause cumulative 
myelotoxic effects and immune suppression. 
Thus, new therapeutic approaches are needed.
Tiacci and colleagues found that the V600E 
mutation of BRAF, a kinase commonly mutated 
in solid tumors,9 was the key genetic lesion of 
hairy-cell leukemia,10,11 and Chung et al. found 
that this mutation is acquired in the hematopoi-
etic stem-cell compartment.12 Tiacci et al. found 
that, as in other BRAF-mutated neoplasms,13 the 
V600E mutation in hairy-cell leukemia constitu-
tively activates the mitogen-activated protein ki-
nase (MAPK) pathway.14,15 The same group found 
that BRAF inhibitors in vitro16 reverse the unique 
molecular signature2 and morphologic charac-
teristics of hairy cells and potently induce their 
apoptosis, thus establishing BRAF V600E as an 
attractive therapeutic target in hairy-cell leuke-
mia. Moreover, the antileukemic activity of BRAF 
inhibitors has been reported anecdotally in pa-
tients with this cancer.17,18
We conducted two phase 2, multicenter clini-
cal trials — in Italy and the United States — to 
investigate the efficacy and safety of an oral 
BRAF inhibitor, vemurafenib,19 in patients with 
relapsed or refractory hairy-cell leukemia. The 
enrollment of patients in the Italian trial was 
completed in April 2013, and the median follow-
up is almost 2 years after the end of treatment. 
The enrollment of the patients in the U.S. trial 
has not yet been completed, but the primary end 
point (overall response rate) has already been met. 
Here we report the results of these two trials.
Me thods
Patients
In the Italian trial, 28 patients were enrolled 
(Table S1 in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org). 
All the patients met one of the following criteria: 
disease that was refractory to a purine analogue, 
defined as no response or a relapse within 1 year 
after treatment (6 patients); early relapse after 
treatment with a purine analogue, defined as re-
lapse that occurred between 1 and 2 years after 
the first course or within 4 years after a second 
or later course (20 patients) or in any case (re-
gardless of timing) in which there was consider-
able bone marrow hypoplasia at the time of re-
lapse (1 patient); or severe side effects from a 
previous purine analogue (1 patient). Eligible 
patients also had to have a hemoglobin level of 
less than 11.0 g per deciliter, a neutrophil count 
of less than 1500 per cubic millimeter, or a plate-
let count of less than 100,000 per cubic millimeter. 
The diagnosis was confirmed centrally by two of 
the authors with the use of annexin A1 immunos-
taining of a bone marrow–biopsy specimen,20 
detection of BRAF V600E by an allele-specific 
polymerase-chain-reaction (PCR) assay,11 and 
flow cytometry. Further details are provided in 
the study protocol, available at NEJM.org.
In the U.S. trial, 26 patients have been en-
rolled (Table S2 in the Supplementary Appendix). 
All the patients met one of the following criteria: 
disease that was refractory to a purine analogue 
(as defined above; 1 patient); early relapse (be-
tween 1 and 2 years) after the first course of a 
purine analogue (1 patient); or two or more re-
lapses that occurred more than 2 years after a 
third or later course of a purine analogue (24 pa-
tients). Eligible patients had to have a hemoglo-
bin level of 10.0 g per deciliter or less, a neutro-
phil count of 1000 per cubic millimeter or less, 
or a platelet count of 100,000 per cubic millimeter 
or less. The presence of BRAF V600E was as-
sessed by means of immunohistochemical testing, 
PCR assay or Sanger sequencing, or the Memo-
rial Sloan Kettering Cancer Center IMPACT as-
say21 (the IMPACT assay was performed in all the 
patients) in a Clinical Laboratory Improvement 
Amendments–certified laboratory. Further details 
are provided in the study protocol.
Study Design
The Italian trial was a phase 2, single-group, 
multicenter study sponsored by the Institute of 
Hematology, University of Perugia, and designed 
by the first and penultimate authors. Roche pro-
vided an unconditional research grant and ve-
murafenib at no cost. Otherwise, Roche had no 
role in the study. The planned enrollment of 28 
patients was completed in 11 months (May 20, 
2012, through April 23, 2013) at eight centers. 
Patients received oral vemurafenib at a dose of 
960 mg twice daily for a minimum of 8 weeks 
and, if they did not have a complete response, 
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for a maximum of 16 weeks (Fig. S1 in the 
Supplementary Appendix). The first 3 patients 
received vemurafenib for 20 weeks. The primary 
end point was the rate of complete response. 
Secondary end points included the time to re-
sponse, relapse-free survival, and safety. We also 
evaluated the overall response rate, progression-
free survival, treatment-free survival (i.e., from 
the last vemurafenib dose until the initiation of 
further antileukemic treatment), and pharmaco-
dynamic biomarkers.
The U.S. trial is an ongoing phase 2, single-
group, multicenter study that was designed by 
the second and last authors. The role of Roche is 
the same as that in the Italian trial. The patients 
were enrolled consecutively from January 2013 
through February 2015 at six sites. Patients re-
ceived oral vemurafenib at a dose of 960 mg twice 
daily, on a continuous schedule for 12 weeks. 
Patients with residual disease (as assessed by 
means of morphologic or immunohistochemical 
testing for CD20, PAX5, DBA44, and tartrate-
resistant alkaline phosphatase) were allowed to 
receive vemurafenib for up to 12 additional 
weeks. The primary end point was the overall 
response rate after 12 weeks of treatment with 
vemurafenib. Secondary end points were overall 
survival, progression-free survival, time to re-
lapse, and pharmacodynamic outcomes.
In the two trials, treatment with vemurafenib 
was allowed at the time of disease relapse, 
which was defined as peripheral-blood counts 
that were low enough to meet the respective 
initial eligibility criteria. Retreatment was per-
mitted for up to 12 weeks (in the Italian trial) or 
until disease progression or occurrence of an 
unacceptable level of toxic effects (in the U.S. 
trial).
Study Assessments
Adverse events were graded according to the 
National Cancer Institute Common Terminology 
Criteria for Adverse Events, version 4.03. Neo-
plastic cutaneous lesions were surgically excised, 
but their presence did not mandate dose modi-
fications.
In the Italian trial, assessments of response 
(blood counts, spleen size, bone marrow biopsy, 
and aspirate) were conducted monthly during 
treatment, together with a dermatologic exami-
nation, and every 3 months during follow-up 
(except for the bone marrow evaluation, which 
was performed every 6 months). Bone marrow 
and peripheral-blood samples were assessed cen-
trally at the Institute of Hematology, University 
of Perugia. The calculation of the Hairy Cell 
Index (the percentage of hematopoietic cellular-
ity multiplied by the percentage of leukemic 
cells, as assessed on the basis on CD20 immunos-
taining, and divided by 10,000) in the bone 
marrow–biopsy specimen has been described 
previously.22
In the U.S. trial, bone marrow assessments 
were performed after 1 and 3 months of vemu-
rafenib treatment and at the end of treatment. 
For patients who had splenomegaly at enroll-
ment, computed tomography of the abdomen 
was performed at baseline and at 3 months. All 
the patients underwent dermatologic examina-
tion at baseline, after 1 month of vemurafenib 
treatment, and every 3 months thereafter until at 
least 1 year after discontinuation of the drug.
In the two trials, the assessment of a com-
plete response required the resolution of any 
cytopenias (as defined by the eligibility criteria 
in each of the two studies) , the absence of evi-
dence of hairy cells in the peripheral blood and 
in bone marrow–biopsy specimens as assessed 
by means of nonimmunologic stains, and the 
absence of splenomegaly. The assessment of a 
partial response required the resolution of cyto-
penias, a reduction in splenomegaly of at least 
50%, and a reduction of at least 50% in leuke-
mic-cell infiltration in both the bone marrow 
and peripheral blood. In the two trials, relapse 
after a complete or partial response was defined 
as the reappearance of cytopenia on at least two 
consecutive occasions (the first of which was 
considered to be the date of relapse).
Pharmacodynamic Analyses
Changes in the morphologic features of the leu-
kemia cells during vemurafenib exposure and 
bone marrow ERK phosphorylation at the end of 
treatment (as assessed by two investigators in a 
blinded manner) were evaluated as described 
previously.14,16 The leukemia disease burden was 
assessed by means of serial flow cytometric 
analysis of peripheral-blood mononuclear cells 
(PBMCs) or bone marrow mononuclear cells.5,23 
DNA from PBMCs was used to quantify the BRAF 
V600E allele burden with the use of a droplet 
digital PCR assay. Soluble interleukin-2–receptor 
alpha (IL2RA) and interleukin-1 receptor type II 
were measured in serum.24 Targeted genomic 
analysis was performed in PBMCs as described 
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previously.25 Further details are provided in the 
Methods section in the Supplementary Appendix.
Statistical Analysis
A Simon’s minimax two-stage design26 was ad-
opted in the two trials. In the Italian study, we 
calculated a sample size that would be sufficient 
to accept the alternative hypothesis (complete 
response rate, ≥30%) and reject the null hypoth-
esis (complete response rate, ≤10%) in an inten-
tion-to-treat analysis, at an alpha level of 0.05 
and a beta level of 0.2. Enrollment was closed in 
April 2013, when the prespecified number of 
patients (28 patients) had been enrolled.
In the U.S. study, the primary end point was 
the overall response rate at 12 weeks. A Simon’s 
minimax two-stage design was used to differen-
tiate between a promising response rate of 40% 
and an unpromising rate of 20%. In the initial 
stage of the study, we determined that a total of 
19 patients had to be enrolled; if 4 or more pa-
tients had a response, the study would continue 
enrolling, with a target final sample of 36 pa-
tients. The study would be considered a success 
if at least 11 of the 36 patients had a response. 
Type I and type II errors were both 0.10. Because 
of promising results (24 patients with a response), 
this report includes data on the first 26 patients 
enrolled.
In the two trials, survival was estimated with 
the use of the Kaplan–Meier method. In the Ital-
ian study, differences in the rate of survival were 
assessed by means of a two-sided log-rank test. 
In the U.S. study, the time to relapse was evalu-
ated with the use of cumulative incidence func-
tions that treated death in the absence of relapse 
as a competing risk.
The change in hairy-cell leukemia cells in 
peripheral blood and bone marrow and the ratio 
of BRAF V600E to BRAF wild-type DNA concen-
tration at 12 weeks were evaluated with the use 
of a paired Student’s t-test. Full details of the 
statistical analysis are provided in the Supple-
mentary Appendix.
R esult s
Patients
The characteristics of all 54 patients are shown 
in Table 1 and in Tables S1 and S2 in the Supple-
mentary Appendix. Six patients in the Italian 
study and 1 in the U.S. study had disease that 
was refractory to a purine analogue; these pa-
tients had undergone a median of 2.5 prior 
therapies and 1 prior therapy, respectively, be-
fore vemurafenib treatment. Patients who had an 
early or repeated relapse after treatment with a 
purine analogue (20 patients in the Italian study 
and 25 patients in the U.S. study) had received a 
median of 4 prior therapies and 3 prior therapies, 
respectively. A total of 54% of the patients in the 
Italian study (15 of 28 patients) and 41% of 
those in the U.S. study (9 of 22) had disease that 
was refractory to the immediate prior therapy.
In the Italian trial, 26 of 28 patients com-
pleted the planned treatment (median duration 
of treatment, 16 weeks; range, 8 to 20). A total 
of 2 patients discontinued the study treatment at 
or before 1 week, owing to acute myocardial in-
farction (in 1 patient), which was considered by 
Characteristic
Italian Trial 
(N = 28)
U.S. Trial 
(N = 26)
Age — yr
Median 57 62
Range 27–84 44–80
No. of previous therapies
Median 3 3
Range 1–12 1–8
Disease refractory to immediate prior 
therapy — no./total no. (%)
Yes 15/27 (56) 9/22 (41)
No 12/27 (44) 13/22 (59)
Prior splenectomy — no. (%)
Yes 8 (29) 5 (19)
No 20 (71) 21 (81)
Hairy-cell involvement in bone marrow — %*
Median 82.5 80
Range 4–95 25–100
Absolute neutrophil count — ×10−3/mm3
Median 0.8 0.8
Range 0.2–5.7 0.2–4.8
Hemoglobin — g/dl
Median 12.2 10.5
Range 8.2–17.0 8.2–14.4
Platelet count — ×10−3/mm3
Median 70 78
Range 6–306 26–238
*  The percentage of hairy-cell involvement in bone marrow was determined with 
the use of immunohistochemical testing.
Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.
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the investigator to be unrelated to the study drug, 
and to withdrawal of consent after a drug-related 
event of grade 3 reversible pancreatitis (in 1).
In the U.S. trial, 24 of 26 patients received the 
study treatment for a median of 18 weeks (range, 
12 to 24). One patient died from progressive 
pneumonia (which was considered by the inves-
tigator to be unrelated to the study drug) after 
23 days of treatment, and another patient with-
drew consent after 4 weeks owing to a drug-
related event of grade 3 reversible photosensitivity.
Response Rate
The overall response rates were 96% (25 of 26 
patients who could be evaluated) in the Italian 
study and 100% (24 of 24) in the U.S. study. The 
unusual presenting features of the one patient 
who did not have a response are described in the 
Results section in the Supplementary Appendix.
The rates of complete response were similar 
in the two trials, as were the rates of partial 
response. In the Italian study, after a median of 
8 weeks, 35% of the patients (9 of 26) had a 
complete response and 62% (16 of 26) had a 
partial response (Table S1 in the Supplementary 
Appendix). Among the patients with a complete 
response, 1 had primary refractory disease, and 
among those with a partial response, 5 had pri-
mary refractory disease. A total of 4 patients 
with a complete response and 10 with a partial 
response had disease that was resistant to the 
last prior treatment.
The median time to recovery of the platelet 
count (≥100,000 per cubic millimeter) was 
2 weeks, the median time to recovery of the 
neutrophil count (≥1500 per cubic millimeter) 
was 4 weeks, and the median time to recovery of 
the hemoglobin level (≥11.0 g per deciliter) was 
8 weeks. Reversion of symptomatic splenomega-
ly and clearance of leukemia cells from the 
blood (as assessed by means of cytomorphologic 
testing) usually occurred within 2 weeks after 
the start of treatment. A substantial decrease in 
leukemic-cell infiltration into bone marrow was 
observed at the earliest time point evaluated 
(4 weeks) (data not shown). However, in all the 
patients with a complete response, immunohisto-
chemical testing showed minimal residual dis-
ease (≤10% of leukemic cells) at the end of treat-
ment (Fig. 1A and 1B).
In the U.S. trial, after 12 weeks of vemu-
rafenib treatment, 42% of the patients (10 of 
24 patients) had a complete response and 58% 
(14 of 24) had a partial response (Table S2 in the 
Supplementary Appendix). Most patients had 
recovery of the neutrophil count (>1000 per cu-
bic millimeter), the hemoglobin level (>10.0 g 
per deciliter), and the platelet count (>100,000 
per cubic millimeter) by 28 days (Fig. 2A). 
Among the 10 patients who received vemu-
rafenib at a twice-daily dose of 480 mg for more 
than 4 weeks, rates of complete response (40%) 
and partial response (60%) were similar to those 
observed among patients who received the stan-
dard dose.
In unplanned exploratory analyses in the two 
studies, treatment duration did not appear to 
influence the type of response (see the Supple-
mentary Appendix). In addition, the rate of com-
plete response was not associated with status 
with regard to prior splenectomy, burden of bone 
marrow disease, refractoriness of the disease to 
the last treatment, or number of prior therapies 
(Tables S1 and S2 in the Supplementary Appen-
dix, and data not shown).
Response Duration
In the Italian study, the median follow-up of the 
25 patients who had a response was 23 months 
(range, 7 to 28) after the last vemurafenib dose. 
The median relapse-free survival was 9 months; 
the relapse-free survival was significantly longer 
among patients who had a complete response 
than among those who had a partial response 
(19 months vs. 6 months; hazard ratio for re-
lapse, 0.26; 95% confidence interval [CI], 0.10 to 
0.68; P = 0.006) (Fig. 1C). The median treatment-
free survival was 21.5 months in all 26 patients 
who could be evaluated, and (with the limitation 
of small numbers) it did not differ significantly 
between the group of patients who had a com-
plete response and the group of those who had 
a partial response (25 months and 18 months, 
respectively; P = 0.21) (Fig. 1C).
Of the 20 patients who had a relapse (5 pa-
tients after a complete response and 15 after a 
partial response), 7 did not require therapy at a 
median of 15 months (range, 4 to 18) after re-
lapse, because their cytopenias were stably mild 
(median hemoglobin level, 14.2 g per deciliter 
[range, 12.4 to 17.5]; median neutrophil count, 
1122 per cubic millimeter [range, 938 to 1724]; 
median platelet count, 86,000 per cubic millimeter 
[range, 63,000 to 269,000]). Conversely, in 13 of 
the 20 patients who had a relapse, cytopenia 
worsened, necessitating antileukemic treatment 
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Figure 1. Extent and Duration of Response in the 25 Patients Who Had a Response to Vemurafenib in the Italian Trial.
Panel A shows hematoxylin and eosin staining of a bone marrow–biopsy specimen from a patient. The image shows infiltration by hairy-
cell leukemia (HCL) cells with wide, clear cytoplasm that is recognizable by morphologic testing at baseline (left side) but not after 8 weeks 
of vemurafenib treatment (right side). Panel B shows CD20 immunostaining of the same bone marrow–biopsy specimen. The image 
shows approximately 75% leukemic-cell infiltration at baseline (left side) and only a few (≤10%) residual scattered hairy cells after 8 weeks 
of vemurafenib treatment (right side). Panel C shows the rate of relapse-free survival (left side) and rate of treatment-free survival (right 
side) among patients who had a complete response or a partial response. The tick marks indicate censored data.
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at a median of 5 months (range, 0 to 16) after 
relapse.
A total of 5 of 25 patients (4 patients with a 
complete response and 1 with a partial re-
sponse) had not had a relapse as of the last fol-
low-up assessment (23 to 25 months after the 
end of treatment). Of the 4 patients with a com-
plete response, 3 had no morphologic evidence 
of hairy-cell leukemia in their last bone mar-
row–biopsy specimen at 13, 19, and 24 months, 
respectively, whereas the fourth patient did not 
have a complete response on histologic testing at 
12 months but did have normal blood counts at 
the last follow-up (24 months).
Figure 2. Effect of Vemurafenib on Peripheral-Blood Counts, Survival, Percentage of Hairy Cells in Peripheral-Blood and Bone Marrow 
Mononuclear Cells, and BRAF V600E Allele Burden in the U.S. Study.
Panel A shows the median absolute neutrophil count, hemoglobin level, and platelet count in the 24 patients who could be evaluated 
over time after the initiation of vemurafenib treatment. Error bars indicate the highest and lowest values observed, and shading indicates 
the normal reference range. Panel B shows the probability of progression-free survival and overall survival for all 26 patients. Tick marks 
 indicate censored data. Panel C shows the mean (±SE) percentage of HCL cells in peripheral-blood and bone marrow mononuclear 
cells over time, as assessed by means of flow cytometry. The mean percentage of HCL cells decreased with each period of vemurafenib 
therapy shown (P<0.05 for all comparisons with the pretreatment values for each time point during therapy). Panel D shows the ratio of 
the concentration of BRAF V600E alleles to the BRAF wild-type alleles on a log10 scale in DNA from peripheral-blood mononuclear cells 
obtained before vemurafenib treatment and after 3 months of therapy. The ratios are shown as box-and-whisker plots; the middle bar 
indicates the median value, the ends of the boxes the interquartile range, and the ends of whiskers the highest and lowest values.
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In unplanned exploratory analyses, relapse-
free survival and treatment-free survival did not 
differ significantly between the group of 18 pa-
tients who received additional treatment after 
having their best response and the group of 7 
patients who did not receive additional treat-
ment, or between the group of 14 patients who 
required a dose reduction and the group of 11 
who did not (data not shown). However, the 7 
patients who underwent splenectomy had a 
shorter relapse-free survival than did those who 
did not undergo splenectomy (median, 6 months 
vs. 11 months; hazard ratio for relapse, 3.55; 
95% CI, 1.04 to 12.06; P = 0.04) and shorter 
treatment-free survival (median, 11 months vs. 
25 months; hazard ratio, 6.61; 95% CI, 1.56 to 
28.00; P = 0.01).
In the U.S. trial, among survivors at the time 
of data cutoff, the median follow-up from the 
first vemurafenib dose was 11.7 months (range, 
1.3 to 25.4). At 1 year, the rate of progression-
free survival was 73% (95% CI, 55 to 97) and the 
rate of overall survival was 91% (95% CI, 79 to 
99) (Fig. 2B). Disease progression occurred in 7 
of 24 patients (29%), including 3 patients who 
had had a complete response and 4 who had had 
a partial response (Table S2 in the Supplemen-
tary Appendix). At 1 year after response, the 
cumulative incidence of relapse was 27% (95% 
CI, 7 to 51). In both trials, vemurafenib retreat-
ment at the time of relapse produced some re-
sponses (see the Supplementary Appendix).
Adverse Events
Table 2 lists the drug-related adverse events of 
grade 2 or higher that were observed in at least 
1 patient in either trial. Table S3 in the Supple-
mentary Appendix list all the adverse events of 
any grade in the Italian trial, including those 
that were not considered by the investigator to 
be related to the study drug. Table S4 in the 
Supplementary Appendix lists drug-related ad-
verse events in the U.S. trial that occurred in 
more than 5% of the 26 patients, as well as all 
adverse events of secondary neoplasms.
In both trials, common vemurafenib-related 
adverse events, mostly of grade 1 or 2 and all 
reversible, included toxic events of the skin (es-
pecially rash and photosensitivity), arthralgias or 
arthritis, pyrexia, and an elevated bilirubin level. 
Other relatively frequent drug-related adverse 
events (recorded in one or both studies) were skin 
papillomas, alopecia, palmar or plantar hyper-
keratosis or dysesthesia, and fatigue, as well as an 
increase in the serum lipase level (which in 2 pa-
tients was associated with grade 3 pancreatitis) 
and elevated levels of aminotransferases, alkaline 
phosphatase, or fibrinogen.
In the Italian study, cutaneous basal-cell carci-
nomas developed in two patients (including one 
patient who had a history of basal-cell carcinoma) 
and a cutaneous superficial melanoma developed 
in one patient, all during treatment with vemu-
rafenib. In the U.S. study, cutaneous squamous-
cell carcinomas developed in three patients (all 
of whom had a history of squamous-cell carci-
noma) and a cutaneous basal-cell carcinoma 
developed in one patient. All these tumors were 
managed by simple excision.
A slight transient decrease in the hemoglobin 
level was noted in 10 patients in the Italian study 
within the first 6 weeks of treatment. Neutrope-
nia was noted in 1 patient in the U.S. study.
In the Italian trial, the planned dose of vemu-
rafenib (960 mg administered twice daily) was 
reduced for at least 3 weeks in 17 instances, in-
volving 15 of 26 patients (58%), to 720 mg twice 
daily (9 patients), 480 mg twice daily (3 patients), 
or 240 mg twice daily (3 patients). Toxic effects 
that led to these dose reductions were mainly 
rash (in 6 patients) and increased creatinine or 
bilirubin level, arthralgia, pancreatitis, and pal-
mar and plantar dysesthesia (in 1 patient each).
In the U.S. trial, 13 patients (50%) required 
reductions in the dose to 720 mg twice daily (2 
patients), 480 mg twice daily (10 patients), or 
240 mg twice daily (1 patient). Adverse events 
leading to dose modifications were arthralgia 
(in 5 patients), rash (in 5), photosensitivity (in 1), 
neutropenia (in 1), and elevations of the aspar-
tate or alanine aminotransferase levels (in 1).
Pharmacodynamic Analyses and Resistance 
Mechanisms
Hairy-cell leukemia cells that are exposed to 
vemurafenib in vitro down-regulate CD25 and 
lose their surface projections.16 Flow cytometry 
in blood and bone marrow consistently showed 
a loss of surface CD25 in a large fraction of leu-
kemia cells at one or more time points during 
therapy in 15 of 19 patients (79%) who could be 
evaluated in the Italian study (including 1 patient 
for whom data have already been reported16) 
(Fig. 3A). This finding suggests that the mea-
surement of surface or soluble CD25 may under-
estimate the residual burden of hairy-cell leuke-
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mia during vemurafenib treatment. In 1 patient 
with marked lymphocytosis, leukemic cells 
showed a clear smoothing of the cell membrane 
2 and 3 days after the initiation of vemurafenib 
(Fig. 3B).
In 13 of 26 patients in the Italian study, a 
bone marrow–biopsy specimen obtained the day 
after the completion of therapy could be evalu-
ated for phosphorylated ERK and PAX5 double 
immunostaining. In 6 of the 13 patients (all of 
whom had a partial response), residual hairy 
cells (PAX5 positive) that were still expressing 
phosphorylated ERK were observed, despite pro-
longed exposure (16 to 20 weeks) to vemurafenib 
(Fig. 3C). In 7 of the 13 patients (2 patients with 
a complete response and 5 with a partial re-
sponse after 12 to 20 weeks of treatment), re-
sidual leukemic cells did not detectably express 
phosphorylated ERK (Fig. 3C). In a post hoc 
exploratory analysis, the median progression-
free survival was 8 months (range, 5 to 13) in 
patients with residual phosphorylated ERK–pos-
itive leukemic cells and 13 months (range, 8 to 
24) in patients without such cells (hazard ratio 
for disease progression, 10.33; 95% CI, 2.10 to 
50.81; P = 0.004).
The residual disease, as measured by the 
Hairy Cell Index (ranging from 0 to 1, with 
Event Italian Trial (N = 28) U.S. Trial (N = 26)
Grade 2 Grade 3 Total Grade 2 Grade 3 Total
number of patients (percent)
Arthralgia or arthritis 10 (36) 2 (7) 12 (43) 8 (31) 0 8 (31)
Rash or erythema 11 (39) 2 (7) 13 (46) 11 (42) 5 (19) 16 (62)
Cutaneous basal-cell carcinoma 2 (7)† 0 2 (7) 1 (4) 0 1 (4)
Cutaneous superficial melanoma 0 1 (4) 1 (4) 0 0 0
Cutaneous squamous-cell carcinoma 0 0 0 3 (12)‡ 0 3 (12)
Skin papilloma 2 (7) 0 2 (7) 0 0 0
Photosensitivity reaction 2 (7) 0 2 (7) 0 2 (8) 2 (8)
Hyperkeratosis 3 (11) 0 3 (11) 0 0 0
Panniculitis 2 (7) 0 2 (7) 0 0 0
Pancreatitis 1 (4)§ 2 (7) 3 (11) 0 0 0
Increased pancreatic enzymes 1 (4) 1 (4) 2 (7) 0 0 0
Hyperbilirubinemia 2 (7) 1 (4) 3 (11) 3 (12) 0 3 (12)
Any increased aminotransferase 1 (4) 0 1 (4) 3 (12) 1 (4) 4 (15)
Increased alkaline phosphatase 0 0 0 0 2 (8) 2 (8)
Pain in the hands or feet 2 (7) 0 2 (7) 2 (8) 0 2 (8)
Headache 1 (4) 0 1 (4) 0 0 0
Increased blood creatinine 2 (7) 0 2 (7) 1 (4) 0 1 (4)
Seborrheic keratosis 2 (7) 0 2 (7) 0 0 0
Asthenia 1 (4) 0 1 (4) 0 2 (8) 2 (8)
Musculoskeletal pain 1 (4) 0 1 (4) 0 0 0
Abdominal pain 1 (4) 0 1 (4) 0 0 0
Pyrexia 0 0 0 0 1 (4) 1 (4)
Nausea 0 0 0 1 (4) 0 1 (4)
Alopecia 0 0 0 1 (4) 0 1 (4)
*  The adverse events listed here occurred in at least one patient in either trial. No grade 4 events were reported in either study.
†  In one patient, two basal-cell carcinomas developed; the other patient had a history of basal-cell carcinoma.
‡  All three patients had a history of squamous-cell carcinoma.
§  The patient with grade 2 pancreatitis in the Italian trial had an elevated lipase or amylase level (or both) but did not have clinical symptoms 
or radiologic abnormalities.
Table 2. Drug-Related Adverse Events of Grade 2 or Higher.*
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higher values indicating greater leukemic infil-
tration), was higher in patients with persistent 
phosphorylated ERK in leukemic cells than in 
those with undetectable expression of phos-
phorylated ERK in leukemic cells (mean Hairy 
Cell Index, 0.139 vs. 0.054; P = 0.03 by a two-
sided Mann–Whitney test). Thus, persistent ERK 
phosphorylation in residual hairy cells at the end 
of treatment may indicate a greater burden of 
residual disease and shorter progression-free 
survival, which suggests that reactivation of 
MEK and ERK is a resistance mechanism to ve-
murafenib.
In the U.S. trial, before vemurafenib treat-
ment, the mean percentage of leukemic cells in 
PBMCs and bone marrow mononuclear cells as 
assessed by means of flow cytometry was 16.0% 
and 16.8%, respectively. These values decreased 
to 3.4% and 6.9%, respectively, after 4 weeks of 
treatment (Fig. 2C) and to 0.7% and 4.2%, re-
spectively, by 12 weeks (P<0.05 for all compari-
sons). The percentage of hairy cells in bone 
marrow decreased even further after 24 weeks to 
a mean of 1.3% (Fig. 2C). Likewise, the droplet 
digital PCR assay, which was performed to 
quantify the concentration of molecules with 
mutated BRAF V600E DNA, revealed a decrease 
by a factor of more than 100 in the BRAF V600E 
allele burden in PBMCs after 12 weeks of vemu-
rafenib therapy (P<0.001 for the comparison 
with the pretreatment value) (Fig. 2D). Consis-
tent with this finding, phosphorylated ERK1/2 
rapidly decreased in bone marrow–biopsy speci-
mens after 4 weeks of vemurafenib therapy (Fig. 
S3A in the Supplementary Appendix).
Finally, in all the patients, serum levels of 
soluble IL2RA and interleukin-1 receptor type II, 
which are well-established biomarkers of hairy-
cell leukemia,27,28 declined markedly, as com-
pared with baseline, by a mean of 30% and 27%, 
respectively, within 24 hours after the initiation 
of vemurafenib. After 3 months, the mean levels 
had declined by at least 95% (Fig. S3B and S3C 
in the Supplementary Appendix).
In one patient in the U.S. study who had dis-
ease that was refractory to vemurafenib retreat-
ment, targeted sequencing of 300 genes (Table 
S6 in the Supplementary Appendix) identified 
two separate activating subclonal KRAS muta-
tions (along with a new RUNX1 mutation) at the 
time of relapse after the initial vemurafenib 
treatment, in addition to the recurrence of the 
BRAF V600E mutation. KRAS mutations had not 
been seen before vemurafenib treatment or at 
remission (day 120) despite high KRAS sequenc-
ing coverage (range, 496× to 1165×) (Fig. 4B, and 
Table S5 in the Supplementary Appendix). Be-
cause in BRAF V600E–mutant cancers activating 
RAS mutations represent a known mechanism of 
vemurafenib resistance by means of the rephos-
phorylation of MEK and ERK,29 the KRAS muta-
tions that were newly acquired in this patient at 
relapse, although subclonal, probably contribut-
ed to the subsequent insensitivity to vemurafenib 
(Fig. 4C).
Discussion
In these two trials involving patients with hairy-
cell leukemia, an oral course of vemurafenib (at 
Figure 3 (facing page). Phenotypic and Molecular Changes 
of HCL Cells during Treatment with Vemurafenib  
in the Italian Trial.
Panel A shows flow-cytometry dot plots of a patient’s 
bone marrow aspirate that was gated on CD45 cells. At 
baseline, CD25 was expressed by 94% of leukemic cells 
(top row, CD19+ and CD103+; bottom row, CD19+ and 
CD25+). A progressive loss of CD25 expression (but not 
of CD19 or CD103 expression) is seen over treatment 
periods of 7 days and 14 days (decreasing to 21% at  
7 days and 12% at 14 days). The remaining cells (red 
dots) are normal CD45+ hematopoietic cells. In Panel B, 
May–Grünwald–Giemsa staining of a patient’s periph-
eral-blood smear (at left) shows leukemic cells rich in 
hairy projections at baseline (top) but not after 2 days 
of vemurafenib treatment (bottom). Confocal fluores-
cence microscopic analysis of blood leukemic cells pu-
rified from the same patient (at right) shows prominent 
surface projections (stained green by phalloidin) at base-
line (top) but not after 3 days of vemurafenib treatment 
(bottom). These changes are evident in electronically 
magnified two-dimensional images (left column) and 
reconstructed three-dimensional fluorescence images 
(right column) of representative cells. Panel C shows 
double immunostaining of a bone marrow–biopsy 
specimen obtained the day after the end of treatment 
and double-stained for PAX5 (a B-cell marker; brown) 
and phosphorylated ERK (pERK; blue). In some patients 
with a response, the persistence of pERK-positive leuke-
mic hairy cells was observed (left side), whereas in other 
patients (right side), residual hairy cells did not detect-
ably express pERK, with stromal cells strongly positive 
for pERK as an internal positive control.
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a dose of 960 mg twice daily for 16 to 18 weeks) 
was rapidly and highly effective, with response 
rates of 96% in the Italian study and 100% in the 
U.S. study and with low-grade toxic effects in 
patients who not only were heavily pretreated 
but often had disease that was refractory to their 
last therapy (56% of patients in the Italian study 
and 41% of those in the U.S. study). The median 
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time to response was 8 weeks in the Italian trial; 
the response rate was assessed at 12 weeks in 
the U.S. trial. A longer duration of treatment did 
not appear to improve the type or duration of 
the response. Retreatment with vemurafenib at 
the time of relapse was effective in the two tri-
als, although to a lesser extent in the patients 
who had a relapse after a partial response than 
in those who had a relapse after a complete re-
sponse in the Italian study.
Rather than administering vemurafenib for 
an indefinite duration, as is done in patients with 
metastatic melanoma,30-32 we limited the initial 
vemurafenib treatment to a few months (even if 
this perhaps reduced the type or duration of re-
sponse) owing to concern about vemurafenib-
induced secondary tumors.33-35 Although such 
tumors affect primarily the skin and are of low 
malignant potential, their development may be 
less acceptable in patients with an indolent leu-
kemia (however refractory or multiply relapsed) 
than in those with metastatic melanoma.
The rate, type, and duration of response that 
we observed among patients with hairy-cell leuke-
mia were superior to those that have been ob-
served in patients with metastatic melanoma,30-32 
possibly owing to the less complex genome 
landscape of hairy-cell leukemia (dominated by 
BRAF V600E10) and the much lower proliferative 
index (≤1% of proliferating cells) of hairy-cell 
leukemia as compared with metastatic melano-
ma.36,37 However, in the U.S. trial, residual hairy 
cells in bone marrow with their associated BRAF 
V600E allele burden were consistently present at 
the end of treatment, even after a complete re-
sponse. In approximately half the patients who 
could be evaluated in the Italian study, these 
cells showed persistent expression of phosphory-
lated ERK despite prolonged ongoing exposure 
to vemurafenib, which appeared to correlate with 
a higher burden of residual leukemia and shorter 
progression-free survival. This finding suggests 
that, in at least some patients, leukemic cells 
develop alternative mechanisms for reactivating 
MEK and ERK to bypass BRAF blockade.
In vitro studies conducted by the Italian group 
suggest that the bone marrow microenvironment 
might oppose vemurafenib-induced ERK dephos-
phorylation and apoptosis.16 It was proposed38 
that as hairy cells pass through the vitronectin-
rich splenic red pulp, they receive vitronectin-
mediated proapoptotic signals that are trans-
duced by activation of p38 and Jun N-terminal 
kinase (JNK) but are overcome by concomitant 
antiapoptotic signals from the constitutive acti-
vation of MEK and ERK. We found that prior 
splenectomy appeared to be associated with a 
shorter duration of response. Thus, a lack of 
hairy-cell recirculation through the spleen, re-
sulting in their continuous homing to the pro-
tective bone marrow microenvironment, may 
favor the persistence of ERK phosphorylation in 
leukemic cells at the end of treatment — a fea-
ture that is also apparently associated with a 
shorter duration of response. Furthermore, two 
activating KRAS mutations developed in one pa-
tient in the U.S. trial who had a relapse, which 
probably contributed to disease progression dur-
ing vemurafenib retreatment.
Vemurafenib-related adverse events were man-
ageable and were similar to those observed in 
patients with melanoma (e.g., rash, arthralgias, 
and secondary cutaneous tumors). The absence 
of clinically significant myelotoxic effects makes 
vemurafenib an ideal salvage treatment for pa-
tients with multiply relapsed hairy-cell leukemia 
who have pancytopenia and scarce bone marrow 
reserve owing to previous chemotherapies.
In anecdotal cases, lower doses of vemu-
rafenib (e.g., 240 mg twice daily) from the be-
ginning of treatment proved effective in patients 
with relapsed or refractory hairy-cell leukemia.17 
Figure 4 (facing page). Activating KRAS Mutations 
 Associated with the Development of Acquired  Vemurafenib 
Resistance in BRAF V600E–Mutated HCL, as Assessed 
by Serial Genomic Analysis.
One patient in the U.S. study had disease that was re-
fractory to vemurafenib retreatment and underwent 
targeted sequencing of 300 genes. Panel A shows the 
serial flow-cytometric analysis of HCL cells in peripheral-
blood mononuclear cells (PBMCs) from this patient 
throughout the initial course of therapy (days 0 to 180) 
and vemurafenib retreatment (days 260 to 320). The 
sectioned-off areas in the fluorescence-activated cell-
sorting plots indicate HCL cells (CD19 and CD103), with 
percentages of HCL cells among the PBMCs. Panel B 
shows the somatic mutations that were identified in 
PBMCs after 0, 120, and 260 days of vemurafenib treat-
ment. The variant allele frequency is shown for muta-
tions seen at each time point. Panel C shows the per-
centage of HCL cells in peripheral blood (left axis) and 
the total white-cell count (right axis) in this patient. 
Shaded areas represent the periods of vemurafenib 
treatment and retreatment. The dashed lines at the 
bottom of the graph indicate the upper and lower limits 
of a normal white-cell count.
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In our studies, the starting dose of 960 mg twice 
daily was reduced only if an unacceptable level 
of toxic effects occurred; in most cases, the dose 
was reduced to a twice-daily dose of 720 mg (in 
the Italian study) or 480 mg (in the U.S. study), 
followed sometimes by reescalation. Prospective 
clinical trials are needed to formally evaluate 
toxicity, response rate, and survival with lower 
vemurafenib doses or longer treatment durations 
than those we used in these trials. Clinical trials 
are also warranted to evaluate the other clinical 
BRAF inhibitor, dabrafenib, which in vitro stud-
ies by the Italian group16 and single case re-
ports18,39 have suggested to be effective in refrac-
tory or relapsed hairy-cell leukemia.
We used vemurafenib as single agent. How-
ever, BRAF inhibitors could be combined with 
anti-CD20 monoclonal antibodies (e.g., rituximab) 
to potentially eradicate BRAF inhibitor–resistant 
hairy-cell leukemia cells. The finding of MAPK-
pathway reactivation as a likely mechanism of 
resistance to vemurafenib in some patients also 
establishes a rationale for combined BRAF and 
MEK blockade, which has been used success-
fully in patients with metastatic melanoma.40
In conclusion, we found that vemurafenib is an 
active targeted drug for patients with relapsed or 
refractory hairy-cell leukemia.
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